UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130

Benzinga Newsdesk www.benzinga.com Positive 73.6%

Neg 0% Neu 0% Pos 73.6%

UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $100 to $130.